Latest & greatest articles for warfarin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on warfarin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on warfarin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for warfarin

81. An alternative to warfarin for patients with PE

An alternative to warfarin for patients with PE An alternative to warfarin for patients with PE Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics An alternative to warfarin for patients with PE View/ Open Date 2012-12 Format Metadata Abstract Consider treating patients with acute pulmonary embolism (PE) with rivaroxaban (...) , a factor Xa inhibitor; it works as well as low-molecular-weight heparin (LMWH) followed by warfarin, but may cause fewer major bleeds. Stength of recommendation: B: Based on a single, nonblinded randomized controlled trial. URI Part of Citation Journal of Family Practice, 61(12) 2012: 751-752. Rights OpenAccess. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License. Collections hosted by hosted by

2014 PURLS

82. Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients With Atrial Fibrillation. Full Text available with Trip Pro

Factor Xa Inhibitors vs Warfarin for Preventing Stroke and Thromboembolism in Patients With Atrial Fibrillation. Is treatment with factor Xa inhibitors associated with better efficacy and safety compared with the vitamin K antagonist warfarin for preventing strokes or other systemic embolic events in patients with atrial fibrillation?Compared with warfarin, factor Xa inhibitors are associated with a lower risk of stroke and other systemic embolic events in patients with atrial fibrillation (...) . Factor Xa inhibitors were associated with lower rates of intracranial hemorrhage and mortality compared with warfarin. Factor Xa inhibitors were associated with a reduction in major bleeding events, but there was heterogeneity between the included studies, and the reduction was not statistically significant in a prespecified sensitivity analysis.

2014 JAMA

83. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. Full Text available with Trip Pro

Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. Conflicting evidence exists regarding the association between warfarin treatment, death, and ischemic stroke incidence in patients with advanced chronic kidney disease (CKD) and atrial fibrillation.To study outcomes associated with warfarin treatment in relation to kidney function among patients with established cardiovascular disease and atrial fibrillation.Observational (...) , prospective, multicenter cohort study from the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry (2003-2010), which includes all Swedish hospitals that provide care for acute cardiac diseases. Participants included consecutive survivors of an acute myocardial infarction (MI) with atrial fibrillation and known serum creatinine (N = 24,317), including 21.8% who were prescribed warfarin at discharge

2014 JAMA

84. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin Full Text available with Trip Pro

High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin The aim of this study was to evaluate the prognostic value of high-sensitivity troponin T (hs-TnT) in addition to clinical risk factors and the CHA2DS2VASc (congestive heart failure, hypertension, 75 years of age and older, diabetes mellitus, previous stroke or transient ischemic attack, vascular disease, 65 to 74 years of age, female) risk score in patients (...) with atrial fibrillation (AF).The level of troponin is a powerful predictor of cardiovascular events and mortality.A total of 14,897 patients with AF were randomized to treatment with apixaban or warfarin in the ARISTOTLE (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation) trial. The associations between baseline hs-TnT levels and outcomes were evaluated using adjusted Cox regression models.Levels of hs-TnT were measurable in 93.5% of patients; 75% had levels >7.5 ng/l, 50% had

2014 EvidenceUpdates Controlled trial quality: predicted high

85. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness

Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism (...) : a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low-molecular weight heparins versus warfarin for the long-term prevention or treatment of deep vein thrombosis or pulmonary embolism: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies

2014 Health Technology Assessment (HTA) Database.

87. Warfarin

Warfarin USE OF WARFARIN IN PREGNANCY 0344 892 0909 USE OF WARFARIN IN PREGNANCY (Date of issue: December 2017 , Version: 3 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Warfarin is a coumarin anticoagulant and vitamin K antagonist which acts by inhibiting clotting factors II, VII, IX and X. It is indicated (...) for: the prevention of systemic embolism in patients with rheumatic heart disease and atrial fibrillation, prophylaxis after insertion of prosthetic heart valves, prophylaxis and treatment of venous thrombosis and pulmonary embolism, and treatment of transient cerebral ischaemic attacks. Fetal warfarin syndrome (FWS) or warfarin embryopathy, characterised by nasal hypoplasia and skeletal abnormalities, including short limbs and digits, and stippled epiphyses, is a well-recognised complication of first trimester

2014 UK Teratology Information Service

88. Cohort study: Prothrombin complex concentrate safely reverses warfarin-related bleeding

Cohort study: Prothrombin complex concentrate safely reverses warfarin-related bleeding Prothrombin complex concentrate safely reverses warfarin-related bleeding | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional (...) accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Prothrombin complex concentrate safely reverses warfarin-related bleeding Article Text Aetiology Cohort study Prothrombin complex concentrate safely reverses warfarin-related bleeding Huyen Tran 1 , Sanjeev Chunilal 2

2014 Evidence-Based Medicine

89. Edoxaban versus Warfarin in Patients with Atrial Fibrillation. Full Text available with Trip Pro

Edoxaban versus Warfarin in Patients with Atrial Fibrillation. Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.We conducted a randomized, double-blind, double-dummy trial comparing two once-daily regimens of edoxaban with warfarin in 21,105 patients with moderate-to-high-risk atrial fibrillation (median follow-up, 2.8 years). The primary (...) efficacy end point was stroke or systemic embolism. Each edoxaban regimen was tested for noninferiority to warfarin during the treatment period. The principal safety end point was major bleeding.The annualized rate of the primary end point during treatment was 1.50% with warfarin (median time in the therapeutic range, 68.4%), as compared with 1.18% with high-dose edoxaban (hazard ratio, 0.79; 97.5% confidence interval [CI], 0.63 to 0.99; P<0.001 for noninferiority) and 1.61% with low-dose edoxaban

2013 NEJM Controlled trial quality: predicted high

90. Preoperative discontinuation of Warfarin for dental surgery not indicated for most patients

Preoperative discontinuation of Warfarin for dental surgery not indicated for most patients UTCAT2600, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Preoperative Discontinuation of Warfarin for Dental Surgery Not Indicated for Most Patients Clinical Question In patients being treated with warfarin, should anticoagulant treatment routinely be interrupted before undergoing dental extractions or is local hemostasis (...) an adequate method to reduce risk of excessive bleeding? Clinical Bottom Line Patients being therapeutically anti-coagulated with warfarin (at an International Normalized Ratio (INR) of less than 4), can undergo dental extractions without discontinuation of anticoagulant therapy considering proper local hemostatic measures are used. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Rodriguez-Cabrera/2011

2013 UTHSCSA Dental School CAT Library

91. An update of consensus guidelines for warfarin reversal Full Text available with Trip Pro

An update of consensus guidelines for warfarin reversal An update of consensus guidelines for warfarin reversal | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset  close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement (...) close An update of consensus guidelines for warfarin reversal Huyen A Tran, Sanjeev D Chunilal, Paul L Harper, Huy Tran, Erica M Wood and Alex S Gallus, on behalf of the Australasian Society of Thrombosis and Haemostasis Med J Aust 2013; 198 (4): 198-199. || doi: 10.5694/mja12.10614 Published online: 4 March 2013 Topics Abstract , Therefore, strategies to manage over-warfarinisation and warfarin during invasive procedures are important. , Despite the associated bleeding risk, warfarin remains

2013 MJA Clinical Guidelines

92. Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. Full Text available with Trip Pro

Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear.In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance (...) of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically relevant nonmajor bleeding.A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism. Among patients receiving warfarin, the time in the therapeutic range was 63.5%. Edoxaban was noninferior

2013 NEJM Controlled trial quality: predicted high

93. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Full Text available with Trip Pro

Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation Harrington AR, Armstrong EP, Nolan PE, Malone DC Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of new oral anticoagulants, for stroke prevention, in patients with nonvalvular atrial fibrillation, compared with warfarin. The authors concluded that the anticoagulants were more cost-effective than warfarin, and apixaban was preferred. The study

2013 NHS Economic Evaluation Database.

94. Warfarin initiation nomograms for venous thromboembolism. (Abstract)

Warfarin initiation nomograms for venous thromboembolism. Venous thromboembolism (VTE) is a common condition in hospital patients. Considerable controversy is ongoing regarding optimal initial warfarin dosing for patients with acute deep venous thrombosis (DVT) and pulmonary embolism (PE). Achieving a therapeutic international normalized ratio (INR) with warfarin as soon as possible is important because this minimizes the duration of parenteral medication necessary to attain immediate (...) anticoagulation, and it potentially decreases the cost and inconvenience of treatment. Although a 5-mg loading-dose nomogram tends to prevent excessive anticoagulation, a 10-mg loading-dose nomogram may achieve a therapeutic INR more quickly.To evaluate the efficacy of a 10-mg warfarin nomogram compared with a 5-mg warfarin nomogram among patients with VTE.The Cochrane Peripheral Vascular Diseases Group Trials Search Co-ordinator searched the Specialised Register (last searched January 2013) and the Cochrane

2013 Cochrane

95. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Full Text available with Trip Pro

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. VKORC1 and CYP2C9 are important contributors to warfarin dose variability, but explain less variability for individuals of African descent than for those of European or Asian descent. We aimed to identify additional variants contributing to warfarin dose requirements in African Americans.We did a genome-wide association study of discovery and replication cohorts. Samples from African (...) -American adults (aged ≥18 years) who were taking a stable maintenance dose of warfarin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the University of Alabama at Birmingham (Birmingham, AL, USA). Patients enrolled at IWPC sites but who were not used for discovery made up the independent replication cohort. All participants were genotyped. We did a stepwise conditional analysis, conditioning first for VKORC1 -1639G→A, followed by the composite genotype of CYP2C9*2

2013 Lancet

96. Point-of-Care Testing of the International Normalized Ratio (INR) for Patients Taking Warfarin or Other Vitamin K Antagonists

Point-of-Care Testing of the International Normalized Ratio (INR) for Patients Taking Warfarin or Other Vitamin K Antagonists Point-of-Care Testing of the International Normalized Ratio (INR) for Patients Taking Warfarin or Other Vitamin K Antagonists | CADTH.ca Find the information you need Point-of-Care Testing of the International Normalized Ratio (INR) for Patients Taking Warfarin or Other Vitamin K Antagonists Point-of-Care Testing of the International Normalized Ratio (INR) for Patients (...) Taking Warfarin or Other Vitamin K Antagonists Published on: April 18, 2013 Project Number: OP0515 Product Line: Result type: Report CADTH has undertaken an optimal use project to assess the clinical and economic impact of point-of-care (POC) testing of the international normalized ratio (INR) for patients taking warfarin or other vitamin K antagonists. Patients with atrial fibrillation, prosthetic heart valves, or venous thromboembolism may be prescribed oral anticoagulation therapy (OAT

2013 CADTH - Optimal Use

97. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. Full Text available with Trip Pro

Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism.In two double-blind, randomized trials, we compared dabigatran at a dose of 150 mg twice daily with warfarin (active-control study) or with placebo (placebo-control study) in patients with venous thromboembolism who had completed at least 3 initial months (...) of therapy.In the active-control study, recurrent venous thromboembolism occurred in 26 of 1430 patients in the dabigatran group (1.8%) and 18 of 1426 patients in the warfarin group (1.3%) (hazard ratio with dabigatran, 1.44; 95% confidence interval [CI], 0.78 to 2.64; P=0.01 for noninferiority). Major bleeding occurred in 13 patients in the dabigatran group (0.9%) and 25 patients in the warfarin group (1.8%) (hazard ratio, 0.52; 95% CI, 0.27 to 1.02). Major or clinically relevant bleeding was less frequent

2013 NEJM Controlled trial quality: predicted high

98. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable

Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable Coleman CI, Straznitskas AD, Sobieraj DM, Kluger J, Anglade MW Record Status (...) atrial fibrillation, who were 65 years old, had a low risk of bleeding, and were unsuitable for warfarin. Patients had a Congestive heart failure, Hypertension, Age, Diabetes, and Stroke (CHADS 2 ) score of two. Interventions Clopidogrel, 75mg per day, plus aspirin, 75mg to 100mg per day, was compared with aspirin alone. Location/setting USA/out-patient secondary care. Methods Analytical approach: A Markov model was constructed of the ongoing risk of stroke, myocardial infarction and adverse events

2013 NHS Economic Evaluation Database.

99. Warfarin vs New Oral Anticoagulants (NOACs) in Non-valvular AFib

Warfarin vs New Oral Anticoagulants (NOACs) in Non-valvular AFib Anticoagulation in Non-valvular 26 AFib www.RxFiles.ca COUMADIN PRADAXA XARELTO ELIQUIS LIXIANA SAVAYSA USA Warfarin Dabigatran 150mg Rivaroxaban Apixaban Edoxaban Stroke/Embolism ? 1 ??? 2 ?? 3 ??? 4 ??? 5 ICH X ? 6 ? 7 ? 8 ? 9 Major GI Bleed ? X 10 X 11 ? 12 X 13 Major Bleed ? ? 14 ? 15 ?? 16 ?? 17 Manage Bleed ? 14 ? 18 X? X? X? MI ? X? 19 -? -? -? DC Rate / Dyspepsia - X 20 /?GI - ? - Low renal fx (CrCl) ?? 21 CI 70%. 1 (...) ) Stroke/Embolism: absolute differences minimal when INR control with warfarin reasonable (TTR=>65%). 2) Stroke/Embolism: Dabi 150mg BID vs Warf; NNT=88/~2yr; ITT (no difference with 110mg BID dose, but less bleeding); open label RCT. (Study pop: renal fx 30+, adherence likely better than normal conditions, etc.) 3) Stroke/Embolism: Riva 20mg daily vs Warf; non-inferiority trial design (ITT analysis favoured Riva but did not achieve superiority); double-blind RCT. (Study pop: limitations similar to RE

2013 RxFiles

100. RE?LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation

RE?LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation RXFILES TRIAL SUMMARY ORIGINALLY PREPARED BY: Z.DUMONT, D.BUNKA. REVISED BY L.KOSAR – UPDATED AUG 2013 – WWW.RXFILES.CA Page 1 of 5 RE-LY: Dabigatran versus Warfarin in Patients with Atrial Fibrillation 1 Randomized Evaluation of Long-term anticoagulation therapY in patients with atrial fibrillation & who were at increased risk of stroke BOTTOM LINE In RE-LY, patients with atrial fibrillation (AF) (mean CHADS 2 score 2.1 (...) ): ? Dabigatran both doses had less hemorrhagic strokes & intracranial bleeds. ? Dabigatran 150mg po bid had: - less stroke/systemic embolism 1 ? endpoint, but more gastrointestinal (GI) bleeds compared to warfarin & dabigatran 110mg po bid - a better net clinical benefit compared to warfarin - more major bleeding than dabigatran 110mg po bid but similar to warfarin ? Dabigatran 110mg po bid was similar to warfarin for stroke & systemic embolism, but had less major bleeding than warfarin. - consider

2013 RxFiles